A carregar...
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia
Adults with relapsed/refractory B-acute lymphoblastic leukemia (ALL) have a complete remission (CR) rate of 20–45% and median overall survival of 3–9 months, depending on the duration of the first remission and number of lines of salvage therapy. Allogeneic hematopoietic stem cell transplantation (a...
Na minha lista:
Publicado no: | Ther Adv Hematol |
---|---|
Main Authors: | , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
SAGE Publications
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4872177/ https://ncbi.nlm.nih.gov/pubmed/27247755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716640422 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|